NCT03132181View on ClinicalTrials.gov

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

January 23, 2019

Study Completion Date

January 23, 2019

Conditions
Diabetes Mellitus Type 2 (T2DM)
Interventions
DRUG

Empagliflozin

Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day

OTHER

Placebo

Patient will be treaded according to standard care but additionally take one tablet placebo per day

Trial Locations (1)

52074

Department of Internal Medicine I RWTH Aachen University Hospital, Aachen

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

RWTH Aachen University

OTHER